Brief: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy
25/09/2024 22:46
Sept 25 (Reuters) - Abivax SA ABVX.PA :
* ABIVAX PROVIDES UPDATE ON ULCERATIVE COLITIS (UC)
COMBINATION
THERAPY PROGRAM STRATEGY AND ANNOUNCES EARLY PRECLINICAL
COMBINATION DATA OF OBEFAZIMOD AND ETRASIMOD IN INFLAMMATORY
BOWEL DISEASE (IBD) MOUSE MODEL
* ABIVAX SA - TO REPORT ADDITIONAL PRECLINICAL DATA IN Q4
2024
Source text for Eikon: ID:nGNX6GDTRw
Further company coverage: ABVX.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abivax SA
See all newsAbivax shares fall after rival drug data, trader says
France's Abivax H1 net loss widens on higher expenses driven by clinical programs
U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United Rentals
GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate
Europe's STOXX 600 ends week at all-time high on earnings support, soft US jobs data